NavigAID SLE - Protagen Zooms into the Micro Cosmos of Autoimmune Disease
The Protagen SeroTag® process helps to understand complex autoimmune diseases on a molecular basis. Utilizing this diagnostic magnifying glass Protagen has developed NavigAID SLE, which allows the separation and definition of patient subgroups and increases the probability of success in SLE therapy and drug development. Worldwide, approximately 5 million patients are affected by this severe autoimmune disease. Recent clinical developments in SLE have focused especially on inhibiting the activation of autoreactive B-cells thereby reducing autoantibody production.
Former Merck Serono Executive and Protagen Board Member, Bernd Kirschbaum explains: “With the exception of Benlysta, approval for novel drugs for SLE therapy is far behind other autoimmune diseases including Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). One major hurdle may be the observed patient heterogeneity. In order to develop effective and curative therapies it is pivotal to define homogeneous disease subgroups in SLE patients, and the new NavigAID SLE does exactly this.” Stefan Müllner adds, “Our innovative diagnostic technology for the first time separates and defines subgroups in SLE, as such it enables new approaches to successful drug development and should be integrated in any SLE clinical development program.”